Adagene (ADAG) Receivables (2019 - 2021)

Adagene's (ADAG) quarterly Receivables came in at $7.5 million in Q4 2021, up 385.05% on a QoQ basis from $1.5 million in Q2 2021.

Adagene (ADAG) Receivables (2019 - 2021) Analysis & Trends

Adagene (ADAG) has 2 years of Receivables data on file, last reported at $7.5 million in Q4 2021.

On a quarterly basis, Receivables changed N/A year-over-year to $7.5 million in Q4 2021; TTM through Dec 2021 was $7.5 million, a N/A change from a year earlier, with the FY2021 full-year figure at $7.5 million, changed N/A from the prior year.
Receivables for Q4 2021 stood at $7.5 million, up from $1.5 million in the prior quarter.
Over the last five years, Receivables for ADAG reached as high as $7.5 million in Q4 2021 and fell as low as $1.5 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Adagene	198.85 Mn	198.85 Mn	-	-

Download Data